M
Mark E. Cooper
Researcher at University of Queensland
Publications - 1514
Citations - 141899
Mark E. Cooper is an academic researcher from University of Queensland. The author has contributed to research in topics: Diabetes mellitus & Diabetic nephropathy. The author has an hindex of 158, co-authored 1463 publications receiving 124887 citations. Previous affiliations of Mark E. Cooper include University of Cambridge & University of Adelaide.
Papers
More filters
Journal ArticleDOI
Advanced-glycation end products in insulin-resistant states.
TL;DR: The factors thought to be important in both the initiation and exacerbation of the insulin-resistant state are summarized, and the potential role of advanced-glycation end products in this process is examined.
Journal ArticleDOI
Retrospective analysis of the relationships among the test environments of the Southern Queensland sugarcane breeding programme
TL;DR: Retrospective analysis of sugar yield data from multi environment trials (METs) which were part of the sugarcane breeding programme in southern Queensland suggested that some aspects of CxL and clone by crop-year (CxY) interactions were repeatable across years.
Journal Article
Lipocalin-2 induces NLRP3 inflammasome activation via HMGB1 induced TLR4 signaling in heart tissue of mice under pressure overload challenge.
Erfei Song,James Won Suk Jahng,Lisa P. Chong,Hye Kyoung Sung,Meng Han,Cuiting Luo,Donghai Wu,Stellar Boo,Boris Hinz,Mark E. Cooper,Avril A. B. Robertson,Thorsten Berger,Tak W. Mak,Isaac George,P. Christian Schulze,Yu Wang,Aimin Xu,Gary Sweeney +17 more
TL;DR: New mechanistic insight is provided on the detrimental role of lipocalin-2 in the development of cardiac dysfunction and evidence of increased inflammasome activation and reduced autophagy in cardiac biopsy samples from heart failure patients is found.
Journal ArticleDOI
Is there a role for pancreas transplantation in type 2 diabetes mellitus
TL;DR: In a carefully selected group of patients, long-term glycemic control and allograft function are similar to that observed for pancreas transplants performed for type 1 diabetes.
Journal ArticleDOI
Fine tuning the disassembly time of thermoresponsive polymer nanoparticles.
TL;DR: The nanoparticles designed in this work, through fine control of the polymer chemical composition, have the potential for drug delivery purposes for timed-release of drugs and prodrugs and other wide-ranging applications where timed- release would be beneficial.